secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000926617-23-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health reports Q4 2022 preliminary volumes up 18%; expects $6M cost savings
--------------------------------------------------------------------------------

- Q4 2022 OvaSuite test volume 5,643 (+18% YoY); full-year 2022 volume 21,424 (+23% YoY).
- Achieved previously provided Q4 cash utilization guidance of $6-8 million.
- Anticipates ~$6M in cost savings from staff reductions; does not expect material impact on growth.
- Expanded territories for top field reps; optimizing BioReference co-marketing agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/0000926617-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/awh-20230109x8k.htm
  HTML page:      https://secwatch.observer/filing/0000926617-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer